Journal of Drug Delivery / 2013 / Article / Tab 2

Review Article

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Table 2

Examples of ligands used for targeting of liposomal nanocarriers.

Type of ligandLigandTargetReference(s)

AntibodyAnti-HER2HER2 receptor overexpressed by cancer cells[34, 98, 100]
Anti-CD19CD19 overexpressed in B cell Lymphoma[101]
Nucleosome-specific 2C5 mAbCancer cells surface-bound nucleosomes[32, 102]

ProteinTransferrinTransferrin receptor overexpressed by cancer cells[36, 103]
Interleukin 13 (IL-13)IL-13 receptor overexpressed in human gliomas[104]

PeptideOctreotideSomatostatin receptor type 2 overexpressed by cancer cells[105, 106]
LHRH-derived peptideLHRH receptors overabundant on cancer cells[107]
Arg-Gly-Asp (RGD)αVβ3overexpressed by endothelial tumor cells[108110]

Small moleculeFolateFolate receptor on cancer cells[41, 111]
EstroneEstrogen receptors overexpressed in ovarian and breast cancers[42, 112]
AnisamideSigma receptors overexpressed by cancer cells[113]

SugarMannoseDendritic cells and macrophages to induce an immune response[114, 115]
LactoseAsialoglycoprotein receptors overexpressed by hepatocellular carcinomas[116]

HER2: human epidermal growth factor receptor 2, mAb: monoclonal antibody, LHRH: luteinizing hormone releasing hormone.